Core Insights - Weigao Group (01066) reported its subsidiary Weigao Orthopedics (688161.SH) third-quarter performance for 2024, achieving a revenue of 1.106 billion yuan, a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders was 207 million yuan, reflecting a year-on-year growth of 26.24%, with basic earnings per share at 0.52 yuan [1] - The announcement indicated that the overall execution of orthopedic bulk procurement remained stable, with domestic leading brands increasing their market share [1] Revenue and Profit Performance - The company recorded a revenue of 1.106 billion yuan for the first three quarters, marking a 2.12% increase compared to the previous year [1] - Net profit attributable to shareholders reached 207 million yuan, which is a 26.24% increase year-on-year [1] - Basic earnings per share stood at 0.52 yuan [1] Market and Operational Strategy - The orthopedic bulk procurement execution was reported to be stable during the reporting period [1] - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - This transformation aims to optimize and upgrade the marketing structure, enhance the professionalism and flexibility of the sales team, and significantly improve clinical service levels, leading to sustained growth in revenue and sales volume [1]